BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/23/2022 2:39:01 PM | Browse: 409 | Download: 830
 |
Received |
|
2021-09-06 08:52 |
|
Peer-Review Started |
|
2021-09-06 08:54 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-10-18 08:16 |
|
Revised |
|
2021-11-16 09:50 |
|
Second Decision |
|
2022-05-26 02:27 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-05-28 07:14 |
|
Articles in Press |
|
2022-05-28 07:14 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-05-23 19:04 |
|
Typeset the Manuscript |
|
2022-05-30 09:01 |
|
Publish the Manuscript Online |
|
2022-06-23 14:39 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Senthil Rajappa, Kun-Ming Rau, Palanki Satya Dattatreya, Anant Ramaswamy, Philana Fernandes, Aarohan Pruthi, Rebecca Cheng, Mariusz Lukanowski and Yi-Hsiang Huang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yi-Hsiang Huang, Doctor, MD, PhD, Professor, Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Institute of Clinical Medicine, National Yang-Ming Yang Ming Chiao Tung University School of Medicine, No. 201, Sec 2, Shi-Pai Road, Taipei 112, Taiwan. yhhuang@vghtpe.gov.tw |
| Key Words |
Hepatocellular carcinoma; Alpha-fetoprotein; Prognostic factor; Ramucirumab; Second-line treatment; Survival |
| Core Tip |
Hepatocellular carcinoma (HCC) is the most frequently diagnosed primary tumor of the liver and is usually detected as advanced disease. Identifying any predictive or prognostic factors prior to and during systemic treatment of HCC is critical in determining optimal treatment patterns. Here, we summarize the contributions of the most recently developed treatment options in HCC beyond first line to improve outcomes for these patients. |
| Publish Date |
2022-06-23 14:39 |
| Citation |
Rajappa S, Rau KM, Dattatreya PS, Ramaswamy A, Fernandes P, Pruthi A, Cheng R, Lukanowski M, Huang YH. Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options? World J Hepatol 2022; 14(6): 1074-1086 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i6/1074.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i6.1074 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
